Media Newsroom of

Inolife Sciences Corporation

Follow on Social Network

Inolife is an emerging specialty medical device company focused on developing and commercializing novel needle-free technologies of liquid jet and ballistics-based epidermal drug injection for the pharmaceutical industry.

Inolife Announces New Advisory Board Member

Inolife Announces New Advisory Board Member

Inolife R&D Inc. ("Inolife"), an emerging life science company and innovation leader in comprehensive needle-free injection solutions, is pleased to announce it has named Camillo Ricordi, M.D. to its Advisory Board. "As one of the world's leading diabetes researchers, we…

Inolife Announces Another Partnership in the Medical Cannabis Space With Empower Clinics

Inolife R&D Inc. (“Inolife”), an emerging life science company and innovation leader in comprehensive needle-free injectable solutions, is pleased to announce a national distribution agreement with Empower Clinics Inc., a leading owner, and operator of medical cannabis and wellness clinics in…

Inolife is Joining the Fight to Cure Cancer

Inolife R&D Inc. (“Inolife”), an emerging life science company and an innovation leader in comprehensive and cutting-edge injectable pharma solutions, announces a partnership with the University of Ottawa/Children Hospital of Eastern Ontario Research Institute (CHEO-RI) to work on genetically-engineered viruses…

Inolife Announces the Closing of Its Final Private Placement and the Naming of Dr. John Leombruno to Its Board of Directors

Inolife R&D Inc. (“Inolife”), an emerging life science company and an innovation leader in comprehensive and cutting-edge Injectable Pharma Solutions, is pleased to announce that it has closed its final private placement. The $2 million round was oversubscribed at over $2.5 million.…

Inolife Enters Into Gonadotropin Kinetics Research With Sanzyme

Inolife R&D Inc. (“Inolife”), an emerging life science company and an innovation leader in needle-free injection technologies, today announced that it has entered into an agreement with India-based pharmaceutical manufacturer Sanzyme Private Limited (“Sanzyme”). Under the terms of the agreement,…

Inolife is Getting Closer to Submitting Its Nanojex® Needle-Free Powdered Nanoparticle Drug Delivery System to the FDA

Inolife R&D Inc. (“Inolife”), an emerging specialty medical device company, announced today the receiving of the working pre-production units of its revolutionary Nanojex® powdered nanoparticle needle-free injection technology. The working prototypes were created in collaboration with Precimold Inc. (“Precimold”), a…

Inolife Has Contracted LOK North America to Spearhead Its ISO 13485 Quality Management System Certification and Initiate Its Health Canada Medical Device Licensing

Inolife R&D Inc. (“Inolife”), announces it has partnered with LOK North America to lead its ISO 13485 Quality Management System review and implementation and initiate its Health Canada Medical Device Licensing. Through this partnership, Inolife will continue to maintain the…

Inolife R&D Signs LOI With ADW Diabetes to Make Its Inojex Needle-Free Injector Available to Diabetics in USA

Inolife R&D Inc. (“Inolife”), announces it has entered into a Letter of Intent (“LOI”) with ADW Diabetes LLC. (“ADW”) for the distribution of its Inojex® product to people suffering from Diabetes in the United States. The opportunity to work with…

Inolife R&D Announces the Commencement of Its Public Listing Process to Meet Growing Demand for Its Needle-Free Injection Technologies.

Inolife R&D Announces the Commencement of Its Public Listing Process to Meet Growing Demand for Its Needle-Free Injection Technologies.

Inolife R&D (“Inolife”), is pleased to announce today it aims for the Public Listing of its stocks on the Canadian Securities Exchange (CSE): currently private, the company commenced the listing process for trade on the CSE, by way of a Reverse…

Inolife R&D Signs Letter of Intent With Namaste to Research the Use of Needle-Free Injection Technologies With Medical Cannabis

Inolife R&D Inc. ("Inolife"), is pleased to announce today it has signed a letter of intent with Namaste Technologies Inc. ("Namaste") for trials in the use of Inolife's needle-free technologies for the dosing and administration of medical cannabis. According to…

Login

Or using ePRNews Account

Don't have an account ? Sign Up

Register New Account

Or form here

Already have an account ? Login

Reset Password

Already have an account ? Login